AB Science today announced that its masitinib Phase 2B/3 study (AB12003) in metastatic castrate-resistant prostate cancer (mCRPC) met its predefined primary endpoint

Daniel Sontupe
Market Access

Matt Turner
Patient Affordability

Paul Theisen
Patient Acquisition

David Linetsky
Point-of-Care Marketing

Amy Giles
Increasing Engagement

Brenda Snow
Authentic Patient Voice

Liz Kane
Impactful Strategy

Bud Bilanich
Success Coach

Joey Cohen
Medication Adherence

Stacey Gandler
Brand Nourishment

Frank Burrell
Scientific Storytelling

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Pat Purcell
Meeting Engagement